Adma Biologics

ADMA Rare disease Lead: Approved 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-25

Catalyst timeline

ADMA corporate update2026ADMA corporate update, 2026, routine
ADMA corporate updateAug 2026ADMA corporate update, Aug 2026, material
SG-001 IND filingbefore YE2026SG-001 IND filing, before YE2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

ASCENIV

Immune Globulin Intravenous, Human – slra 10% Liquid · RI-002

Protein Target: RSV neutralizing antibodies

Primary Humoral Immunodeficiency Approved intravenous NCT01814800

Nabi-HB

Hepatitis B Immune Globulin, Human

Protein Target: Hepatitis B antibodies

Hepatitis B Approved intramuscular

S. pneumoniae hyperimmune globulin

SG-001

Protein Target: S. pneumoniae antibodies

Pneumococcal Pneumonia Preclinical

BIVIGAM

Immune Globulin Intravenous, Human

Protein Target: polyclonal antibodies

Primary Humoral Immunodeficiency Approved intravenous NCT00473824

Biotech Distilled coverage (2)

2026-08-06 UPDATE: ADMA Biologics (ADMA) - The Trough Held 🔒 Paid
2026-07-06 ADMA Biologics (ADMA) — Scientific Deep Dive for ASCENIV, BIVIGAM, Nabi-HB, and the SG-001 Pipeline 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.